Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer Journal Article
| Authors: | Milton, D. T.; Miller, V. A. |
| Article Title: | Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer |
| Abstract: | Improvements in drug development and clinical trial design have resulted in a wider range of treatment options for patients with advanced non-small cell lung cancer (NSCLC). Combination chemotherapy is the standard of care for medically fit patients. A variety of chemotherapeutic doublets, including nonplatinum combinations, with similar clinical activity are now available, allowing oncologists to match acceptable toxicity profiles to individual patients' comorbidities and preferences. Single-agent treatment of refractory or recurrent disease has been shown to improve survival and offer improved quality of life (QOL). For special patient populations, such as the elderly and patients with limited performance status (PS), treatment with single-agent chemotherapy results in modest survival benefits and combination chemotherapy may be appropriate for some of these patients. © 2005 Elsevier Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; unclassified drug; clinical trial; fatigue; neutropenia; review; cancer recurrence; cisplatin; erlotinib; diarrhea; side effect; gemcitabine; paclitaxel; cancer patient; neurotoxicity; antineoplastic agent; carboplatin; metastasis; quality of life; nephrotoxicity; neoplasm recurrence, local; bone marrow suppression; etoposide; blood toxicity; lung non small cell cancer; nausea; thrombocytopenia; vomiting; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; peripheral neuropathy; weight reduction; dexamethasone; ifosfamide; docetaxel; irinotecan; antiinfective agent; comorbidity; gefitinib; platinum; vindesine; folic acid; vinca alkaloid; taxane derivative; navelbine; alopecia; pemetrexed; hydration; clinical trials; paclitaxel poliglumex; cyanocobalamin; tirapazamine; ototoxicity; hair loss; paclitaxel derivative; antisense oligonucleotide; isis 3521 |
| Journal Title: | Seminars in Oncology |
| Volume: | 32 |
| Issue: | 3 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2005-06-01 |
| Start Page: | 299 |
| End Page: | 314 |
| Language: | English |
| DOI: | 10.1053/j.seminoncol.2005.02.011 |
| PUBMED: | 15988685 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 6" - "Export Date: 24 October 2012" - "CODEN: SOLGA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work